<http://webisa.webdatacommons.org/399159373>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<patentgenius.com> .
<http://webisa.webdatacommons.org/399159373>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/463996052>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/399159373> .
<http://webisa.webdatacommons.org/prov/450489025>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/399159373> .
<http://webisa.webdatacommons.org/399159373>	<http://www.w3.org/ns/prov#value>	"CF-1 mice following ip-administration;FIGS. 5A and 5B are a graph and bar graph, respectively, which illustrate the transcytosis and accumulation of BBI, BBIssPal(2) and BBIssPal(4) across and into Caco-2 cells; andFIG. 6 is a graph which illustrates the results of Sephadex.RTM. G50 gel filtration analysis of basal medium from Caco-2 cells containing transcytosed BBI, BBIssPal(2) and BBIssPal(4).F" .